Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Forecasted to Post Q1 2023 Earnings of ($4.09) Per Share

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Get Rating) – Equities research analysts at Oppenheimer decreased their Q1 2023 earnings per share (EPS) estimates for shares of Corbus Pharmaceuticals in a note issued to investors on Tuesday, March 7th. Oppenheimer analyst L. Gershell now anticipates that the biopharmaceutical company will post earnings per share of ($4.09) for the quarter, down from their previous forecast of ($2.10). The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($6.54) per share. Oppenheimer also issued estimates for Corbus Pharmaceuticals’ Q2 2023 earnings at ($2.35) EPS, Q3 2023 earnings at ($2.39) EPS, Q4 2023 earnings at ($2.42) EPS, FY2023 earnings at ($11.22) EPS, FY2024 earnings at ($11.34) EPS and FY2025 earnings at ($11.92) EPS.

CRBP has been the subject of a number of other research reports. HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of Corbus Pharmaceuticals in a research note on Wednesday. StockNews.com assumed coverage on shares of Corbus Pharmaceuticals in a report on Monday, February 20th. They set a “sell” rating on the stock.

Corbus Pharmaceuticals Stock Down 9.3 %

Shares of NASDAQ:CRBP opened at $2.14 on Friday. The business has a fifty day simple moving average of $1.17 and a 200 day simple moving average of $0.50. Corbus Pharmaceuticals has a 12-month low of $2.11 and a 12-month high of $18.72. The company has a quick ratio of 3.86, a current ratio of 4.76 and a debt-to-equity ratio of 0.48. The firm has a market cap of $8.92 million, a P/E ratio of -0.21 and a beta of 2.22.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Two Sigma Investments LP grew its position in Corbus Pharmaceuticals by 366.7% in the fourth quarter. Two Sigma Investments LP now owns 570,168 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 448,002 shares in the last quarter. ExodusPoint Capital Management LP bought a new position in Corbus Pharmaceuticals in the third quarter worth about $60,000. Renaissance Technologies LLC raised its stake in Corbus Pharmaceuticals by 40.6% in the second quarter. Renaissance Technologies LLC now owns 1,626,860 shares of the biopharmaceutical company’s stock worth $410,000 after buying an additional 469,669 shares in the last quarter. State Street Corp raised its stake in Corbus Pharmaceuticals by 10.7% in the first quarter. State Street Corp now owns 395,513 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 38,304 shares in the last quarter. Finally, Vident Investment Advisory LLC increased its stake in shares of Corbus Pharmaceuticals by 66.2% during the first quarter. Vident Investment Advisory LLC now owns 255,146 shares of the biopharmaceutical company’s stock valued at $135,000 after purchasing an additional 101,659 shares in the last quarter. 18.65% of the stock is currently owned by hedge funds and other institutional investors.

Corbus Pharmaceuticals Company Profile

(Get Rating)

Corbus Pharmaceuticals Holdings, Inc is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its products include candidate, Lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes.